College Point, New York Clinical Trials

A listing of College Point, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 156 clinical trials
6.14 Program Trial 3 - [over 65 yo]

6.14 Program Trial 3 - [over 65 yo]

TrialX Research Center
 (7.5 away) Contact site
  • 0 views
  • 24 Apr, 2024
  • 1 location
Smoke Testing v6.14.1  

Testing

Formal Site
 (6.0 away)
  • 0 views
  • 14 Jun, 2024
  • +3 other locations
PCSK9i in AAA123  

Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol

Formal Site
 (6.0 away)
  • 0 views
  • 18 Mar, 2025
  • 1 location
Sleep Apnea (CW)

Overview

QA Test1
 (8.3 away) Contact site
  • 0 views
  • 27 Jul, 2025
  • 1 location
UAT Test Trial 0804 (UAT)

UAT Test Trial 0804

Formal Test Site - NY
 (7.5 away) Contact site
  • 0 views
  • 11 Aug, 2025
  • +2 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (6.5 away)
  • 0 views
  • 29 Nov, 2024
  • +19 other locations
UAT Study

Bowen Test Study Overview

Formal Site
 (6.0 away) Contact site
  • 0 views
  • 09 May, 2025
  • +7 other locations
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease  

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

alzheimer's disease
Weill Cornell Medicine
 (6.3 away)
  • 0 views
  • 09 May, 2025
  • +2 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

autologous hematopoietic stem cell transplant
bortezomib
lenalidomide
multiple myeloma
immunotherapeutic agent
Investigational Site Number 8400001
 (5.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations